Memory Science Tech | The Alzheimer's Solution

The System Is Failing

America spends $384 billion a year managing Alzheimer's.
We have a better plan.

Cnstyx is a novel CNS-selective acetylcholinesterase inhibitor that delivers 2× the efficacy of current drugs at 1/26th the cost of new treatments—accessible to every patient, not just the wealthy.

Talk to Our Team → View Investment Thesis

66%

Brain AChE Inhibition

~$1K/yr

Projected Annual Cost

4 Years

To FDA Approval

Animal Tox/Phase I

Current Stage

The Crisis

Current solutions are failing patients, bankrupting families, and collapsing the healthcare system.

$384B

spent annually managing Alzheimer's

101× more than researching cures

7.2M

Americans living with Alzheimer's

Projected: 13M by 2050

92%

of early cases go undiagnosed

Current drugs aren't worth the diagnosis

12M

unpaid family caregivers

Providing $413B in free labor annually

The Solution

Cnstyx isn't incrementally better.
It's categorically different.

Feature

Aricept (Current Standard)

Leqembi (New Drug)

Cnstyx (Our Drug)

Administration

Oral pill

IV infusion every 2 weeks

Oral pill

Annual Cost

$1,095–$9,125

$26,500 + monitoring

~$1,000

Brain Penetration

~30%

N/A

66%

Side Effects

Severe GI issues

10-15% brain swelling risk

Minimal

Prescriber

Any doctor

Neurologist only

Any doctor

Infrastructure

Any pharmacy

Infusion center + MRI monitoring

Any pharmacy

💊

Accessible

Oral pill prescribed by any doctor, available at any pharmacy. No infusion centers, no specialist bottleneck.

💰

Affordable

~$1,000/year vs $26,500 for Leqembi. Works within existing Medicare/Medicaid infrastructure.

🧠

Effective

66% brain AChE inhibition vs 30% for current drugs. Long-lasting improvement that persists after treatment.

Beyond Treatment

Every other Alzheimer's drug treats symptoms after diagnosis.
Cnstyx has prophylactic potential.

High-risk individuals—APOE4 carriers, family history, early MCI—could start Cnstyx before symptoms appear. This isn't disease management. This is disease prevention.

The 99% who want early intervention? Cnstyx is the first drug that makes early intervention medically justified.

The Opportunity

Moderate-risked. Early-stage. Identified for commercialization.

✓

1990s

Preclinical Research

✓

2025

Established Plan

●

2026

Animal Tox/Phase I

2029

FDA Approval

Investment Ask

$25M

To complete Phase I/II and reach FDA approval

Market Opportunity

$1.5B+

Annual sales at 20% market penetration

System Savings

$200B+

Annual healthcare savings if widely adopted

The crisis is massive.
The demand is overwhelming.
The solution is ready.

Cnstyx represents the most de-risked Alzheimer's drug investment available today. Let's discuss how you can be part of ending this crisis.

Schedule a Conversation →

Or email us at [email protected]

America spends $384 billion a year managing Alzheimer's. We have a better plan.

Current solutions are failing patients, bankrupting families, and collapsing the healthcare system.

Cnstyx isn't incrementally better.It's categorically different.

Every other Alzheimer's drug treats symptoms after diagnosis. Cnstyx has prophylactic potential.

Moderate-risked. Early-stage. Identified for commercialization.

The crisis is massive. The demand is overwhelming. The solution is ready.

America spends $384 billion a year managing Alzheimer's.
We have a better plan.

Cnstyx isn't incrementally better.
It's categorically different.

Every other Alzheimer's drug treats symptoms after diagnosis.
Cnstyx has prophylactic potential.

The crisis is massive.
The demand is overwhelming.
The solution is ready.